Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Canaccord Genuity Group

Exagen (NASDAQ:XGN) had its price objective decreased by equities researchers at Canaccord Genuity Group from $15.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 222.58% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. William Blair restated an “outperform” rating on shares of Exagen in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Exagen in a report on Wednesday, January 21st. KeyCorp cut their price objective on Exagen from $15.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday. BTIG Research decreased their target price on Exagen from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, TD Cowen lowered their price target on Exagen from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, February 24th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Exagen has a consensus rating of “Moderate Buy” and an average price target of $9.57.

Exagen Stock Down 4.6%

Shares of XGN stock traded down $0.15 during mid-day trading on Wednesday, reaching $3.10. 269,654 shares of the company were exchanged, compared to its average volume of 522,742. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08. The business’s 50 day simple moving average is $4.24 and its 200 day simple moving average is $7.53. The company has a market capitalization of $70.25 million, a P/E ratio of -3.36 and a beta of 1.88. Exagen has a fifty-two week low of $2.91 and a fifty-two week high of $12.23.

Exagen (NASDAQ:XGN) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). The firm had revenue of $16.63 million for the quarter, compared to analysts’ expectations of $16.46 million. Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. Research analysts predict that Exagen will post -0.88 earnings per share for the current year.

Insiders Place Their Bets

In other Exagen news, CEO John Aballi sold 15,698 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a total value of $56,826.76. Following the transaction, the chief executive officer owned 687,299 shares of the company’s stock, valued at $2,488,022.38. This trade represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 12.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Exagen

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC acquired a new stake in shares of Exagen during the 4th quarter worth approximately $88,000. XTX Topco Ltd lifted its holdings in shares of Exagen by 248.5% in the 4th quarter. XTX Topco Ltd now owns 96,994 shares of the company’s stock worth $590,000 after purchasing an additional 69,161 shares during the last quarter. Occudo Quantitative Strategies LP boosted its position in Exagen by 44.8% during the 4th quarter. Occudo Quantitative Strategies LP now owns 30,214 shares of the company’s stock valued at $184,000 after purchasing an additional 9,346 shares during the period. Man Group plc bought a new position in Exagen during the 4th quarter worth $198,000. Finally, Engineers Gate Manager LP grew its stake in Exagen by 52.9% during the 4th quarter. Engineers Gate Manager LP now owns 62,964 shares of the company’s stock worth $383,000 after buying an additional 21,780 shares during the last quarter. 75.25% of the stock is owned by institutional investors.

Trending Headlines about Exagen

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Management set 2026 revenue guidance of $70–$73M and said it is expanding the sales force and accelerating product innovation — a growth/operational plan that supports longer‑term upside. Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence
• Positive Sentiment: Company reported record full‑year revenue, higher average selling price for its AVISE CTD test and >11% test‑volume growth for 2025 — evidence of demand and pricing leverage. Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
• Neutral Sentiment: Q4 EPS was a ($0.20) loss, in line with expectations, while revenue of $16.63M modestly beat consensus — results show execution but the company remains unprofitable. Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
• Neutral Sentiment: Earnings call transcript and slide deck provide management detail on margin targets, investments and the go‑to‑market plan — useful for assessing cadence of growth and cash burn. Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Guidance slightly below street expectations (company: $70–$73M vs consensus ~$74M) — a modest disappointment that can weigh on near‑term sentiment. Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
• Negative Sentiment: Several brokers trimmed price targets this week (Craig Hallum $12→$10; KeyCorp $15→$10; BTIG $10→$9) — the cuts lower near‑term upside expectations despite retained buy/overweight ratings. Analyst Price Target Changes (Benzinga) Exagen (XGN) PT Lowered to $9 at BTIG
• Negative Sentiment: Short interest rose meaningfully in February (~1.07M shares, ~5.4% of float; ~4 days to cover), increasing downside pressure and volatility risk from short sellers.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.